Targets › IRS1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2030.
Signaling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R. Plays therefore an important role in development, growth, glucose homeostasis as well as lipid metabolism. Upon phosphorylation by the insulin receptor, functions as a signaling scaffold that propagates insulin action through…. (UniProt, P35568)
Open in Phaseline: the race on IRS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Colorado, Denver | NT219 IRS1/2 and STAT3 inhibitor | IRS1, IRS2, STAT3 | Phase 1 | Head and Neck Cancer | Feb 2030 |
Head and Neck Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.